Trial Profile

A Phase I, Randomized, Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Doses of MEMP1972A in Volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Sep 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quilizumab (Primary) ; Quilizumab (Primary)
Indications Seasonal allergic rhinitis
Focus Adverse reactions

Most Recent Events

05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
16 Jul 2012 New trial record
20 May 2012 Results reported at the 108th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com